News
-
-
COMMUNIQUÉ DE PRESSE
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2
Valneva et LimmaTech annoncent la vaccination du premier participant à l’étude pédiatrique de Phase 2 du candidat vaccin tétravalent contre la shigellose S4V2 -
COMMUNIQUÉ DE PRESSE
Valneva and LimmaTech Announce First Vaccination in Phase 2 Infant Study of Tetravalent Shigella Vaccine Candidate S4V2
Valneva and LimmaTech announce first vaccination in Phase 2 infant study of tetravalent Shigella vaccine candidate S4V2. Study aims to combat shigellosis, a deadly diarrheal disease -
COMMUNIQUÉ DE PRESSE
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
Biophytis confirms the launch of the Phase 2 OBA Clinical Trial in Obesity in 2025. The study aims to evaluate the efficacy of BIO101 in reducing muscle strength loss caused by GLP-1 agonists in obese patients -
-
-
-
COMMUNIQUÉ DE PRESSE
Redcare successfully executes placement of new convertible bonds and buys back part of the outstanding convertible bonds.
Redcare Pharmacy N.V. successfully executes placement of new convertible bonds amounting to EUR 300 million with a maturity of seven years and buys back a part of outstanding convertible bonds, strengthening its balance sheet and capital structure -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Redcare Pharmacy N.V. successfully places EUR 300 million convertible bonds and repurchases part of its outstanding EUR 225 million 0.00% convertible bonds due 2028
Redcare Pharmacy N.V. successfully places EUR 300 million convertible bonds and repurchases part of its outstanding EUR 225 million 0.00% convertible bonds due 2028. The company intends to use the net proceeds for general corporate purposes -
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Semperit AG Holding: US tariff policy and lower global order activity lead to adjustment of EBITDA guidance for 2025 – Guidance 2026 suspended due to current high uncertainties
Semperit AG Holding adjusts EBITDA guidance for 2025 due to US tariffs and lower global order activity. Guidance for 2026 suspended
